Over-reliance on β 2-agonists may worsen the clinical course Bronchodilators in asthma: How effective and safe?

Stephen I. Rennard

Research output: Contribution to journalArticle

Abstract

β 2-Agonists, ipratropium, and theophylline relieve asthma symptoms by relaxing bronchial smooth muscle; none have clinically relevant anti-inflammatory properties. Bronchodilators may be used alone for mild, intermittent asthma. However, if symptoms occur more than three times weekly or more than twice monthly at night, use an inhaled anti-inflammatory drug as primary therapy and a shorter-acting inhaled β 2-agonist as a "rescue" medication for breakthrough symptoms. If needed, a long-acting bronchodilator may be added to control nighttime symptoms. Long-term use of bronchodilators as the only therapy for moderate to severe asthma may increase airway responsiveness, cause tolerance, delay recognition of worsening asthma, and prevent timely initiation of anti-inflammatory therapy.

Original languageEnglish (US)
Pages (from-to)S14-S18
JournalJournal of Respiratory Diseases
Volume19
Issue number3 SUPPL.
StatePublished - Dec 1 1998

Fingerprint

Bronchodilator Agents
Asthma
Anti-Inflammatory Agents
Ipratropium
Theophylline
Smooth Muscle
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Over-reliance on β 2-agonists may worsen the clinical course Bronchodilators in asthma : How effective and safe? / Rennard, Stephen I.

In: Journal of Respiratory Diseases, Vol. 19, No. 3 SUPPL., 01.12.1998, p. S14-S18.

Research output: Contribution to journalArticle

@article{a8d6138dcf9540e7aabef1e681c33228,
title = "Over-reliance on β 2-agonists may worsen the clinical course Bronchodilators in asthma: How effective and safe?",
abstract = "β 2-Agonists, ipratropium, and theophylline relieve asthma symptoms by relaxing bronchial smooth muscle; none have clinically relevant anti-inflammatory properties. Bronchodilators may be used alone for mild, intermittent asthma. However, if symptoms occur more than three times weekly or more than twice monthly at night, use an inhaled anti-inflammatory drug as primary therapy and a shorter-acting inhaled β 2-agonist as a {"}rescue{"} medication for breakthrough symptoms. If needed, a long-acting bronchodilator may be added to control nighttime symptoms. Long-term use of bronchodilators as the only therapy for moderate to severe asthma may increase airway responsiveness, cause tolerance, delay recognition of worsening asthma, and prevent timely initiation of anti-inflammatory therapy.",
author = "Rennard, {Stephen I.}",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "19",
pages = "S14--S18",
journal = "Journal of Respiratory Diseases",
issn = "0194-259X",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Over-reliance on β 2-agonists may worsen the clinical course Bronchodilators in asthma

T2 - How effective and safe?

AU - Rennard, Stephen I.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - β 2-Agonists, ipratropium, and theophylline relieve asthma symptoms by relaxing bronchial smooth muscle; none have clinically relevant anti-inflammatory properties. Bronchodilators may be used alone for mild, intermittent asthma. However, if symptoms occur more than three times weekly or more than twice monthly at night, use an inhaled anti-inflammatory drug as primary therapy and a shorter-acting inhaled β 2-agonist as a "rescue" medication for breakthrough symptoms. If needed, a long-acting bronchodilator may be added to control nighttime symptoms. Long-term use of bronchodilators as the only therapy for moderate to severe asthma may increase airway responsiveness, cause tolerance, delay recognition of worsening asthma, and prevent timely initiation of anti-inflammatory therapy.

AB - β 2-Agonists, ipratropium, and theophylline relieve asthma symptoms by relaxing bronchial smooth muscle; none have clinically relevant anti-inflammatory properties. Bronchodilators may be used alone for mild, intermittent asthma. However, if symptoms occur more than three times weekly or more than twice monthly at night, use an inhaled anti-inflammatory drug as primary therapy and a shorter-acting inhaled β 2-agonist as a "rescue" medication for breakthrough symptoms. If needed, a long-acting bronchodilator may be added to control nighttime symptoms. Long-term use of bronchodilators as the only therapy for moderate to severe asthma may increase airway responsiveness, cause tolerance, delay recognition of worsening asthma, and prevent timely initiation of anti-inflammatory therapy.

UR - http://www.scopus.com/inward/record.url?scp=29344440060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344440060&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:29344440060

VL - 19

SP - S14-S18

JO - Journal of Respiratory Diseases

JF - Journal of Respiratory Diseases

SN - 0194-259X

IS - 3 SUPPL.

ER -